NaviCam Magnetically Controlled Capsule Gastroscope System
The NaviCam Magnetically Controlled Capsule Gastroscope System enables complete stomach visualization through a swallowable capsule controlled by external magnetic fields, eliminating the discomfort of traditional intubation while maintaining diagnostic accuracy comparable to conventional gastroscopy. ANKON Technologies described NaviCam as the first commercialized magnetically controlled capsule endoscope when it launched in 2013.
Product Overview
Developed by ANKON Technologies and commercialized in 2013, NaviCam addresses the fundamental limitation of passive capsule endoscopes: inability to systematically examine the stomach’s large cavity. Through precise magnetic navigation, physicians can actively guide the capsule through all gastric regions, adjusting position and viewing angle with millimeter-level precision across five degrees of freedom.
The system serves multiple clinical scenarios including routine health screenings, early gastric cancer detection, evaluation of patients unsuitable for sedation, and monitoring of anticoagulant therapy patients at risk of GI bleeding. Its non-invasive nature has proven particularly valuable for elderly patients with comorbidities, pediatric populations, and individuals who decline traditional endoscopy.
Key Features
Cleared in China since 2013 and FDA-approved in May 2020, NaviCam delivers complete gastric examination through a swallowable capsule guided by up to 200 mT magnetic navigation.
- Active Magnetic Navigation: C-arm robotic guidance generating magnetic fields up to 200 mT enables systematic spiral scanning of all gastric surfaces
- Complete Visualization: Five-dimensional capsule control (rotation, tilt, translation) eliminates blind spots inherent in passive capsule transit
- Real-Time Monitoring: Wireless image transmission to workstation allows immediate physician assessment and navigation adjustment
- Magnetic Position Sensing: Proprietary technology determines capsule location without X-ray verification
- Auto-Focus Capability: Variable focus distance adapts to different viewing conditions and lesion proximity
- No Cross-Infection Risk: Single-use disposable capsule eliminates sterilization concerns
Technical Specifications
Cleared across three jurisdictions, NaviCam’s 11.8 × 27 mm capsule captures 640 × 480 images at up to 12 fps with a 140° field of view over more than 8 hours of battery life.
| Parameter | Specification |
|---|---|
| Capsule Size | 11.8mm × 27mm |
| Capsule Weight | 5g |
| Image Resolution | 640 × 480 pixels (3rd gen) |
| Frame Rate | Up to 12 fps |
| Field of View | 140° |
| Working Time | >8 hours |
| Magnetic Field Strength | Up to 200 mT |
| Examination Duration | ~15 minutes |
Clinical Applications
NaviCam addresses the significant gap between gastric cancer incidence and screening capacity. With China reporting over 400,000 new gastric cancer cases annually and early-stage detection rates below 20%, the need for accessible screening tools is acute. An estimated 560 million individuals fall within recommended screening populations.
Primary applications include:
Asymptomatic Screening: Routine health examinations for individuals over 40 or with family history of gastric cancer
Symptomatic Evaluation: Initial assessment of dyspepsia, epigastric pain, or suspected bleeding in patients preferring non-invasive options
High-Risk Monitoring: Serial examinations for patients with atrophic gastritis, intestinal metaplasia, or prior gastric lesions
Special Populations: Elderly patients with cardiovascular comorbidities, pediatric patients, and individuals with severe gag reflex or sedation contraindications
Post-PCI Surveillance: Cardiac patients on dual antiplatelet therapy at elevated GI bleeding risk
Multi-center RCTs conducted at seven leading Chinese hospitals demonstrated 93.4% diagnostic accuracy and 90.4% sensitivity compared to conventional gastroscopy. The 2024 National Health Commission guidelines formally recommend magnetically controlled capsule gastroscopy for gastric cancer screening programs.
Regulatory Status
| Region | Status | Date | Classification |
|---|---|---|---|
| China (NMPA) | Approved | 2013-01 | Class III |
| European Union (CE) | Approved | - | Class IIa |
| United States (FDA) | Approved | 2020-05 | De Novo |
The FDA De Novo classification established NaviCam as the first magnetically controlled capsule endoscope system cleared for the U.S. market. The indication covers visualization of the stomach in adults aged 22 and older with BMI below 38, approved for use in clinics, hospitals, and emergency room settings.
Frequently Asked Questions
How does NaviCam examination work?
After an overnight fast, the patient swallows the NaviCam capsule with water while lying on the examination table. The physician uses a joystick controller to navigate the capsule through the stomach, systematically viewing the cardia, fundus, body, angulus, antrum, and pylorus. Real-time images display on the workstation monitor. The entire examination typically completes in 15 minutes. The capsule subsequently passes through the digestive tract and is naturally excreted.
Can NaviCam replace traditional gastroscopy?
NaviCam provides comparable diagnostic accuracy for visualization and lesion detection, making it an excellent screening and diagnostic tool. However, it cannot perform biopsies, remove polyps, or conduct therapeutic interventions. Suspicious findings identified during NaviCam examination typically require follow-up conventional endoscopy for tissue sampling or treatment.
What are the contraindications?
Contraindications include known or suspected GI obstruction, strictures, or fistulas; pregnancy; implanted cardiac pacemakers or defibrillators; scheduled MRI examination before capsule passage; and swallowing disorders preventing capsule ingestion. Patients with BMI exceeding 38 are excluded from the FDA-approved indication.
Browse related categories
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.